Vitrase (hyaluronidase), Advanced Corneal Systems, Inc.�s product for treating vitreous hemorrhage, has been given fast-track status by the FDA. This will facilitate development and expedite review of the drug.

Vitrase is currently in Phase II clinical trials in the United States, with Phase III studies expected to be initiated by the end of the year.

Mexico�s National Ministry of Health has granted marketing authorization for the product, to be distributed in Mexico by Sophia Laboratories.

Vitreous hemorrhage clouds sight and makes retinal assessment difficult in 450,000 Americans each year. Diabetes is one of the most common causes.